CMS adopts performance-based standards for CRC biomarker tests; evidence questions linger

CMS established a new national framework setting performance thresholds to qualify noninvasive, biomarker-based colorectal cancer screening options — including FDA-approved stool- and blood-based tests — for coverage.“The CMS coverage decision provides benchmarks for novel noninvasive tests to meet and exceed to gain coverage, and learn from the experience of currently approved